Abbott Laboratories Inc.'s pending $25bn acquisition of St. Jude Medical Inc. will not be deterred by allegations that St. Jude has been irresponsible about cybersecurity protections for its devices or a recent safety advisory warning of the potential for premature battery depletion of its cardiac implants, Abbott's CEO Miles White affirmed.
"I don't see this impacting the close of the deal, or the business long term," White said during his firm's Oct. 19 third-quarter earnings call. "Based on everything I see,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?